Bold Science. Better Outcomes.
At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies.
We are pioneers who rapidly translate discoveries into innovations and innovations into differentiated therapeutic solutions, to address the most significant unmet medical needs in oncology.
We leverage exceptional experience in immunology to swiftly advance our modular, precision biotherapeutics platform to exploit the full potential of the array of unprecedented and validated immuno-oncology targets which comprise our pipeline.
We embrace collaborative team science to drive our success. We are scientifically curious and are highly agile problem-solvers. Our ambitions demand that we always remain both resilient and relentless.
EvolveImmune (EV) was founded to advance groundbreaking immune cell target discovery, originating from the Sidi Chen Laboratory at Yale University. Since our launch in 2020, we have built a fully integrated, world-class immunobiology and biotherapeutics team which is actively confronting the biggest challenges in cancer.
Our approach to changing the course of cancer is simple: durable immune activation, where it matters.
EvolveImmune’s proprietary immunobiologics platform delivers both sustained immune activation and tumor cell targeting in a single agent. Through integrated signaling, EV’s first in category biologics directly target tumor cells and provide potent, tissue-localized amplification of cytokine secretion at the tumor site to maximize tumor killing.
Our biotherapeutics are engineered to overcome limitations of conventional CD3 bispecifics and other immune therapies to offer a better future for our patients in need, by maximizing therapeutic benefit and minimizing toxicity.
Our lead program, EVOLVE-104, is a first-in-category therapeutic with potential to address a wide range of solid tumors with high selectivity. EVOLVE-101 is a first-in-category therapeutic for B cell malignancies and AML. EvolveImmune will move both programs rapidly to clinical trials.
Board of Directors
Scientific Advisory Board
SVP, Global Head Oncology and Hematology Drug Development - Genentech Roche
Former Physician-in-Chief Yale-Smilow Cancer Center
Former SVP Biologics Discovery, Oncology Discovery - Bristol-Myers Squibb
Partnered w/ Jim Allison on CTLA-4 drug development
Leader of the Melanoma/Renal Cancer Translational Team, Former president Society of Immunotherapy in Cancer (SITC)
Working with the best
EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Read More
EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and ImmunotherapyRead More
EvolveImmune Therapeutics to Present New Preclinical Data from Novel Costimulatory T Cell Engager Platform at Upcoming Scientific ConferencesRead More
EvolveImmune Therapeutics Appoints Jay Fine, Ph.D., as President of Research and DevelopmentRead More
The future of immunotherapy starts hereRead More
EvolveImmune Therapeutics Welcomes Ian Taylor, PhD to the Board of DirectorsRead More
Industry vets launch biotech in Branford targeting cancer, autoimmune diseaseRead More
EvolveImmune celebrates opening of state-of-the-art lab and office complex in Branford, ConnecticutRead More
Bold scientists seeking better outcomes for patients.
At EvolveImmune, we are building an exceptional team to bring our ambitions to life. If you are looking for a home for your talents, and you enjoy the camaraderie and hands-on environment of a startup biotechnology company, we invite you to apply.
EvolveImmune offers attractive compensation and benefits including a 401K plan with a generous company match as well as health & wellness benefits.
About Our Locations
It is a short drive to local amenities on the Connecticut shoreline, as well as to New Haven and Yale University. EvolveImmune has additional laboratories in Farmington, Connecticut as part of the UCONN Technology Incubator Program.